Please login to the form below

Not currently logged in

Eisai to transfer US manufacturing campus to Biogen

Willhand over Research Triangle Park facility incapacity-sharing deal


Eisai has transferred ownership of its North Carolina manufacturing campus to Biogen in an expansion of the capacity-sharing deal they signed in 2013.

The change will affect approximately 100 of Eisai's Research Triangle Park employees, who will be offered jobs with Biogen once the deal is complete, but Eisai's Baltimore manufacturing facility will not be affected.

Under the terms of their new agreement Biogen will continue to manufacture oral solid-dose products for Eisai and will now also produce the Japanese company's parenteral products.

Eisai will, however, retain a base in North Carolina, which will continue to be home to its global partnership management, quality assurance, supply chain and business support staff.

At present these functions are housed on the Research Triangle Park campus, where they will remain for the next six months until the company secures new offices for them.

Lou Arp, general manager of the Eisai RTP site and president of the Global Oncology Manufacturing Unit for Eisai Inc, said: "The decision to transfer ownership of the RTP campus is part of a global supply chain initiative to optimise Eisai's logistics strategy in support of our long-term business objectives.

"Eisai and Biogen have had a successful alliance for a number of years. We share a patient-centric culture and have compatible values on how we perform our work. This arrangement is a natural fit and complementary to both companies, ensuring the state-of-the-art RTP facility operates at a higher capacity and jobs stay in North Carolina."

The property ownership transfer includes all Eisai's buildings on the campus, with its parenteral facility to be transferred when the deal closes and the oral solid-dose facility follow after an existing short-term lease expires.

Article by
Dominic Tyer

21st July 2015

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...